news

Award recognises innovative label-free technology

A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.

Stem cell discovery

An award from Frost & Sullivan has recognised a new automated, high-content, label-free single-cell analysis and sorting platform. According to the organisation, the accolade is presented for an innovative element in a product which leverages pioneering technologies.

The 2019 Global New Product Innovation Award was granted to LumaCyte for its Laser Force Cytology™ (LFC™) technology, a part of the Radiance® platform. This is due to its capability to accelerate therapies and analytical insights by enabling new cell discovery, characterisation and phenotyping across a broad range of applications.

The platform can be used for viral quantification, required for assays in vaccine and cell and gene therapy development and production. The technology evaluates single suspended or fixed cells directly without the use of antibody or genetic labelling, which eliminates research bias when investigating changes in cell populations.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

“[This] novel approach empowers the discovery, characterisation and sorting of cells from biological samples based upon their inherent physical, biochemical and biological characteristics. As a result, LumaCyte can offer direct-from-cell sample to analysis/sorting with no antibody staining, processing, antibody-induced phenotype changes or fixation,” said Christi Bird Ulan, Principal Consultant at Frost & Sullivan.

By measuring subtle changes in unique biochemical and biophysical cellular properties, the platform can yield new data and insights to understand cellular systems using optical force, microfluidics, imaging and robust multivariate data. Its label-free applications include gene expression, cell clearance and epigenetics, as well as quality control and process optimisation for biomanufacturing.